Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Cymbalta
|
| gptkbp:activities |
serotonin-norepinephrine reuptake inhibitor (SNRI)
|
| gptkbp:appointed_by |
oral capsule
oral solution |
| gptkbp:approves |
gptkb:2004
gptkb:FDA |
| gptkbp:brand |
gptkb:Cymbalta
Drizalma Sprinkle |
| gptkbp:category |
gptkb:C
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
gptkb:sneaker
allergic reactions severe liver disease severe kidney disease |
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:dosage_form |
gptkb:beer
gptkb:software_framework 120 mg daily 30 mg to 120 mg daily 60 mg daily |
| gptkbp:duration |
daily
as needed |
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
duloxetine
|
| gptkbp:ingredients |
C18 H19 NOS
|
| gptkbp:interacts_with |
gptkb:beer
MAO inhibitors other antidepressants |
| gptkbp:is_available_in |
tablets
liquid form |
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_used_for |
chronic pain
fibromyalgia generalized anxiety disorder major depressive disorder |
| gptkbp:lifespan |
12 hours
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
CY P1 A2
CY P2 D6 |
| gptkbp:performance |
not a controlled substance
|
| gptkbp:side_effect |
dizziness
fatigue nausea hypertension weight loss liver damage withdrawal symptoms insomnia constipation dry mouth weight gain sweating increased heart rate sexual dysfunction bleeding risk serotonin syndrome |
| gptkbp:type_of |
116539-59-4
|